FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
Stocks · News reference
Tandem Diabetes Care shares are trading higher after the company reported better-than-expected Q2 EPS results and reaffirmed its FY2026 sales guidance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating
William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform rating.
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.